americanpharmaceuticalreviewNovember 19, 2020
Tag: Cannabics , RCC-33 , Tumor , human biopsies
Cannabics Pharmaceuticals has completed a pre-clinical study using its proprietary and novel RCC-33 formulation on human biopsies, obtained under a Helsinki Committee approved protocol. The results show an antitumor synergistic effect of the active compounds, thus confirming the company' previously obtained data on the antitumor properties of the drug candidate when screened on colorectal cell lines.
"The study results brings us one step closer in preparing our submission to the U.S. Food and Drug Administration for a pre-IND meeting. Our next step will be launching a study on mice to try and demonstrate the same synergistic effect and see tumor growth attenuation in-vivo," Dr. Eyal Ballan, Cannabics Pharmaceuticals' CTO said.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: